Answers are grounded in this paper and cite their sources.
Phase I study evaluates tolerability, safety, and pharmacokinetics of ARTS-011 in individuals, implying potential for daily use in chronic conditions.
ARTS-011 is a promising oral Tyk2 inhibitor with an acceptable safety profile and potential for once-daily dosing. These results support further clinical development of ARTS-011 in patients with inflammatory and autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: